{"entity":{"id":"nct07233850","kind":"trial","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","aka":[],"tldr":"A phase 2 trial of SSGJ-706, cAPOX (capecitabine, oxaliplatin) and bevacizumab in pancreatic cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., not yet recruiting.","summary":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers is a phase 2, interventional study registered as NCT07233850 by Shenyang Sunshine Pharmaceutical Co., LTD., with a registry enrolment figure of 300 participants, started 2025-11 and due to reach its primary completion in 2026-12. Interventions recorded: SSGJ-706+XELOX; SSGJ-706+Bevacizumab+XELOX; SSGJ-706+AG; SSGJ-706+TP. Conditions listed: Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Oesophageal Cancer. Primary outcome: Incidence and severity of Adverse Events; Objective response rate (ORR). Pancreatic eligibility wording from the registry: \"Locally advanced or metastatic tumors of the digestive system that cannot be curatively resected and cannot be treated with radical chemoradiotherapy, including gastric/gastroesophageal junction adenocarcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and oesophageal cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07233850","url":"https://clinicaltrials.gov/study/NCT07233850"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac","locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["ssgj-706","capox","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07233850","phase":"2","setting":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07233850/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"ssgj-706","kind":"drug","name":"SSGJ-706","route":"/drugs/ssgj-706/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}